{
    "nct_id": "NCT05665062",
    "official_title": "A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies",
    "inclusion_criteria": "1. Histologically confirmed relapsed/refractory hematologic malignancies, including Chronic Lymphocytic Lymphoma (CLL/SLL) and selected Non-Hodgkin's Lymphoma (NHL)\n2. Prior or current documentation of CD19 expression or high likelihood of CD19 expression based on disease histology\n3. No signs of symptoms of central nervous system (CNS) disease or detectable evidence of CNS or meningeal disease on magnetic resonance imaging (MRI) at the time of screening\n\nSelected\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior CD19 directed therapy including CD19 CARTs\n2. Prior allogeneic hematopoietic stem cell transplant within 6 months of enrollment\n3. Prior autologous hematopoietic stem cell transplant within 6 weeks of enrollment.\n4. Presence of GVHD",
    "miscellaneous_criteria": "Selected"
}